Q1 2027 Gufic Biosciences Ltd Earnings Call Transcript
Key Points
- EBITDA margin improved significantly to 18.09% in Q1 FY27 from 14.6% in Q1 FY26, driven by better capacity utilization and product mix.
- PAT more than doubled year-over-year to INR22.46 crore in Q1 FY27, with PAT margin expanding to 8.61% from 5.3%.
- Indore facility is fully operational with new capabilities (depot and microsphere, liposomal antifungal) nearing completion, targeting 40-45% capacity utilization by year-end.
- GLP-1 CMO partnership with Hetero is progressing; Hetero received approvals in May 2026, with revenue traction expected to build from Q2/Q3 FY27.
- International expansion is advancing: secured approvals in 8 countries, executed a contract manufacturing and licensing deal in North America, and received first orders from Australia.
- Botulinum toxin franchise remains #2 in India, with new in-licensed filler portfolio (from Canada) expected to launch by December/January, strengthening the aesthetics division.
- Domestic critical care launched a new monobactam/beta-lactamase inhibitor combination immediately after patent expiry, with encouraging early adoption in large institutions.
- Women's health franchise (Ferticare, Puregraf) secured entry into major corporate IVF chains, and investigator-led studies have begun.
- Management reaffirmed 15-20% year-over-year revenue growth as a 'bare minimum' commitment, with medium-term expectations unchanged.
- Shift to IP-led model in international markets (own registrations, field force) is expected to improve pricing and margins by 15-20% over time.
- Total revenue remained flat year-over-year at INR226.8 crore in Q1 FY27 versus INR226.9 crore in Q1 FY26, indicating no top-line growth.
- PBT margin in Q1 FY27 (11.56%) was lower than Q4 FY26 (10.96%) sequentially, though PAT margin improved slightly.
- Indore facility capacity utilization is still low (around 30-35%), with full operating leverage not expected until mid-FY28.
- GLP-1 CMO revenue is still in early stages; Q1 saw a 10-15 day plant shutdown for new machine installation, delaying traction.
- EU certification for Indore is still pending, which is critical for unlocking European and other regulated market exports.
- Employee costs increased due to a one-time conversion of contract workers to permanent payroll, which may pressure margins in the near term.
- Botulinum toxin export expansion is limited by current facility capacity (WHO Phase 1 only), restricting near-term global growth.
- The filler portfolio launch is dependent on regulatory approvals, which may slip beyond the expected December/January timeline.
- Management was vague on specific revenue contributions from new initiatives (GLP-1, fillers, international), providing only qualitative guidance.
- The company's growth is heavily reliant on product mix improvement and capacity utilization, which carry execution risks.
Ladies and gentlemen, good day, and welcome to Gufic Biosciences Limited Q1 FY27 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand over the conference to Ms. Ami Shah from Gufic Biosciences Limited. Thank you, and over to you, ma'am.
Thank you so much. Good afternoon, everyone. I, Ami Shah, Company Secretary, welcome you all to the investor call of Gufic Biosciences Limited financial results for first quarter of FY26, '27. The press release and investor presentation relating to the results has been submitted to the stock exchange on Friday and are also available on the company's website.
Let me begin by introducing the management team joining us on today's call. We have with us Mr. Pranav Choksi, CEO and Whole-Time Director; Mr. Devkinandan Roonghta, Chief Financial Officer; and Mr. Avik Das, Investor Relations Head.
Before we begin, I would like to remind everyone of the safe harbor statement.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
